Med Spa Exit Readiness: Preparing for the PE Conversation

Private equity has, over the last five years, quietly become the most powerful force in aesthetic medicine. Med spa platforms are consolidating at multiples that would have sounded absurd a decade ago, and the operators who built the practices are getting a window — sometimes a brief one — to capture institutional-grade value for what they have built.

Most owners I work with come to the PE conversation under-prepared, not because they don't have a good business, but because their financials don't tell the story the buyer needs to underwrite. This is a candid look at what makes a med spa actually sellable and the work that meaningfully moves the multiple.

What buyers actually evaluate

Sophisticated buyers — PE platforms, strategic acquirers, MSO operators — are not buying the clinical story. They are buying a financial asset. The diligence runs on five questions: Is the trailing-twelve-month EBITDA real? Is it growing? Is it sustainable without the founder? Is the working capital normal? And are the records clean enough that the deal does not blow up in confirmatory diligence?

Almost every owner I have worked with answers 'yes' to the first three questions reflexively. Almost none can prove it to a buyer without significant retrofit work. The financial retrofit is the readiness work.

The four pieces of the readiness package

Audit-quality historical financials. Cash-basis books are fine for tax. They are not fine for diligence. Buyers expect accrual-basis financials, properly recognized deferred revenue (memberships, packages, gift cards), and at least 24 months of clean monthly history.

Adjusted EBITDA bridge. The honest list of add-backs — owner W-2 above market, owner perks, one-time legal, family on payroll — documented and defensible. A bridge that survives a quality-of-earnings review is worth multiple turns of value versus one that doesn't.

Working capital normalization. The 'normal' level of working capital the buyer expects to inherit at close. Mis-set this number and you can give back six- or seven-figures of price at the closing table.

A real management story. Buyers underwrite the practice without you. Provider compensation, manager bench, and standard operating procedures all need to read like a business, not a hobby — even if you intend to stay through the earn-out.

What actually moves the multiple

Three things, in order. Credibility of the EBITDA — every dollar a buyer trusts is worth more than a dollar they have to interrogate. Membership and recurring revenue mix — closer to subscription economics, closer to a software multiple. And multi-site, multi-provider operating leverage — the buyer is paying for what they can scale, not for what the founder can personally produce.

When to start

The honest answer is 18–24 months before you intend to transact. Readiness work compresses the trailing-twelve-month EBITDA that the buyer prices on, and the multiple is applied to that number. A retrofit done six months before close still helps. A retrofit done 24 months before close can re-rate the business entirely.

This is the single highest-ROI window for a fractional CFO engagement in aesthetic medicine. Not because the work is glamorous — most of it is unsexy — but because the math of compounding clean operating decisions across a 24-month runway is, in this sector, exceptional.